ACHN 14.33 Achillion Pharmaceuticals $ACHN Hit a 5

ACHN 14.33 Achillion Pharmaceuticals $ACHN Hit a 52 week high of 14.65 Closing the day 09:45 at 14.33 -0.52 -3.50% With a day low of 13.93 and a total volume of 1,853,247.

ACHN Recent Posts: http://investorshangout.com/Achillion-Pharmac...CHN-53213/

ACHN Achillion Pharmaceuticals Recent Headline News

Will Achillion Pharmaceuticals (ACHN) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 2 hrs 40 mins ago
Will Achillion Pharmaceuticals (ACHN) Continue to Surge Higher?
ACHN: 14.37 (-0.48)

Nasdaq stocks posting largest percentage increases
AP - Wed Nov 12, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
ESCA: 13.26 (+0.33), RESN: 7.21 (+0.18), OREX: 6.03 (+0.19), OLED: 28.12 (+0.66), ACHN: 14.37 (-0.48), CZR: 14.24 (+0.57), NTIC: 20.78 (+0.03), SUSQ: 13.13 (+0.01)

Achillion Pharmaceuticals: Still Bullish, But Taking Profits
Dr. Paul Nunzio DeSantis, Pharm.D - Seeking Alpha - Wed Nov 12, 4:06PM CST
By Dr. Paul Nunzio De Santis (Pharm.D.) Entry: $9.86 10/2/14 Take Profits: $14.45 11/12/14 Hold 10-20% of profits into event for M&A upside. Achillion (NASDAQ: ACHN ) has been a stellar performer since we wrote about it on October 2nd- up...
ACHN: 14.37 (-0.48), MRK: 59.82 (+0.51), ABBV: 64.20 (+0.44)

Achillion Pharmaceuticals (ACHN) Stock Rises on Positive Hepatitis C Drug Results
at The Street - Wed Nov 12, 10:57AM CST
Shares of Achillion Pharmaceuticals (ACHN) continued to rise Wednesday after the company reported encouraging interim results from a Phase II study of its hepatitis C drug ACH-3102.
ACHN: 14.37 (-0.48)

Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 12, 7:48AM CST
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 116.22 (-0.46), GILD: 105.99 (-0.91), ACHN: 14.37 (-0.48), DNDN: 0.16 (unch), AMGN: 161.61 (-0.32), ABBV: 64.20 (+0.44), REGN: 400.00 (-1.11)

This Tiny Biotech Is Piggybacking on Gilead Sciences, Inc.'s Success
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 7:43AM CST
Source: Gilead Sciences. Developing drugs that help established blockbusters work better is a major trend in biotechnology. It's a lower-stakes game because drug developers only need to show that their products can improve upon existing therapies,...
GILD: 105.99 (-0.91), ACHN: 14.37 (-0.48), MRK: 59.82 (+0.51)

Most active Nasdaq-traded stocks
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
FB: 74.93 (+0.21), ACHN: 14.37 (-0.48), DNDN: 0.16 (unch), CMCSK: 53.89 (+0.49), ARCP: 8.83 (+0.04), ZNGA: 2.85 (+0.04), MSFT: 48.98 (+0.20), INTC: 33.64 (+0.26), GRPN: 8.02 (-0.08), CMCSA: 54.08 (+0.48), AAPL: 112.44 (+1.19), CSCO: 25.48 (+0.37)

Achillion Jumps on Encouraging Data on its HCV Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 4:10PM CST
Shares of Achillion Pharmaceuticals (ACHN) soared over 27% after the company reported encouraging interim results on ACH-3102.
JNJ: 108.98 (+0.23), GILD: 105.99 (-0.91), ACHN: 14.37 (-0.48), AMAG: 35.01 (+0.08)

Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - Tue Nov 11, 10:13AM CST
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 105.99 (-0.91), ACHN: 14.37 (-0.48), MRK: 59.82 (+0.51), ABBV: 64.20 (+0.44), BMY: 57.99 (-0.62)

Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST

JNJ: 108.98 (+0.23), GILD: 105.99 (-0.91), ACHN: 14.37 (-0.48), CNAT: 7.16 (+0.26), MRK: 59.82 (+0.51), RGLS: 18.12 (-1.50), ABBV: 64.20 (+0.44), BMY: 57.99 (-0.62), ENTA: 44.53 (+1.22)

AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST

JNJ: 108.98 (+0.23), GILD: 105.99 (-0.91), ACHN: 14.40 (-0.45), CNAT: 7.16 (+0.26), MRK: 59.82 (+0.51), RGLS: 18.12 (-1.50), ABBV: 64.20 (+0.44), BMY: 57.99 (-0.62), ENTA: 44.53 (+1.22)

Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST

JNJ: 108.98 (+0.23), GILD: 105.99 (-0.91), ACHN: 14.40 (-0.45), CNAT: 7.16 (+0.26), MRK: 59.82 (+0.51), LGND: 57.85 (+0.15), RGLS: 18.12 (-1.50), ABBV: 64.20 (+0.44), BMY: 57.99 (-0.62), ENTA: 44.53 (+1.22)

Critical Alerts For Achillion Pharmaceuticals, Celldex Therapeutics, Kandi Technologies, Illumina and Advanced Micro Devices Released By InvestorsObserver
PR Newswire - Tue Nov 11, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for ACHN, CLDX, KNDI, ILMN and AMD.
KNDI: 13.90 (-0.85), AMD: 2.72 (+0.01), ACHN: 14.40 (-0.45), CLDX: 15.06 (+0.25), ILMN: 191.40 (+4.48)

Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST

JNJ: 108.96 (+0.21), GILD: 106.00 (-0.90), ACHN: 14.40 (-0.45), CNAT: 7.16 (+0.26), LGND: 57.66 (-0.04), RGLS: 18.12 (-1.50), ABBV: 64.20 (+0.44), BMY: 57.99 (-0.62), ENTA: 44.53 (+1.22)

Achillion Pharmaceuticals (ACHN) Looks Strong: Stock Up 27.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:44AM CST
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares surge a little over 27% on the day
HSKA: 16.00 (unch), ACHN: 14.40 (-0.45), ILMN: 191.40 (+4.48), AFFX: 9.79 (+0.01)

Achillion rises on new hepatitis C drug study
AP - Mon Nov 10, 1:17PM CST
NEW YORK (AP) — Shares of Achillion Pharmaceuticals climbed Monday after the company reported clinical trial results for one of its experimental hepatitis C drugs.
GILD: 106.00 (-0.90), ACHN: 14.40 (-0.45)